Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy

Nakamura,Tsutomu; Takahashi,Minoru; Niigata,Riho; Yamashita,Kazuhiko; Kume,Manabu; Hirai,Midori; Yasui,Hiroyuki

doi:10.3892/br.2016.789

Changes in blood concentrations of trace metals in cancer patients receiving cisplatin-based chemotherapy

Authors:
- Tsutomu Nakamura
- Minoru Takahashi
- Riho Niigata
- Kazuhiko Yamashita
- Manabu Kume
- Midori Hirai
- Hiroyuki Yasui
View Affiliations

Affiliations: Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka 569‑1094, Japan, Department of Pharmaceutical Health Care, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hyogo 670‑8524, Japan, Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto 607‑8414, Japan, Department of Pharmacy, Kobe University Hospital, Kobe, Hyogo 650‑0017, Japan
Published online on: October 24, 2016 https://doi.org/10.3892/br.2016.789
Pages: 737-744

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The administration of cisplatin (CDDP) may influence trace metal concentrations in body fluids. In order to test this hypothesis, the blood concentrations of trace metals were determined during the present study in eight Japanese esophageal and lung cancer patients receiving CDDP‑based chemotherapy. The levels of manganese, iron (Fe), cobalt, copper, zinc (Zn), platinum and lead in the plasma were determined by inductively coupled plasma‑mass spectrometry. In addition, the serum levels of Fe, transferrin and ferritin were evaluated. The baseline plasma concentration of Fe in patients with esophageal cancer was significantly lower than that in lung cancer patients (P=0.011), although there were no significant differences identified with respect to the plasma levels of other trace metals. The data obtained from six fasting patients without blood transfusion demonstrated that plasma concentrations of Fe increased 3.5‑fold soon after CDDP treatment and returned to baseline levels ~10 days after therapy. The excessive Fe levels in the bloodstream induced changes in serum ferritin and transferrin levels. Furthermore, serum Zn levels increased 1.8‑fold in the 1‑3 days following CDDP treatment, and serum cystatin C levels transiently increased. These findings indicate that serum Fe and Zn levels may be useful to understanding the physiological responses in the early stages of CDDP‑based chemotherapy, which may be associated with systemic inflammation and/or tissue distribution of CDDP.

View Figures

View References

1	Madias NE and Harrington JT: Platinum nephrotoxicity. Am J Med. 65:307–314. 1978. View Article : Google Scholar : PubMed/NCBI
2	Kintzel PE and Dorr RT: Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev. 21:33–64. 1995. View Article : Google Scholar : PubMed/NCBI
3	Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH and Sparreboom A: Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 86:396–402. 2009. View Article : Google Scholar : PubMed/NCBI
4	Nakamura T, Yonezawa A, Hashimoto S, Katsura T and Inui K: Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol. 80:1762–1767. 2010. View Article : Google Scholar : PubMed/NCBI
5	Moreno-Gordaliza E, Giesen C, Lázaro A, Esteban-Fernández D, Humanes B, Cañas B, Panne U, Tejedor A, Jakubowski N and Gómez-Gómez MM: Elemental bioimaging in kidney by LA-ICP-MS as a tool to study nephrotoxicity and renal protective strategies in cisplatin therapies. Anal Chem. 83:7933–7940. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kume M, Yasui H, Yoshikawa Y, Horinouchi M, Higashiguchi K, Kobayashi Y, Kuroda D, Hirano T, Hirai M and Nakamura T: Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients. Cancer Chemother Pharmacol. 69:1537–1544. 2012. View Article : Google Scholar : PubMed/NCBI
7	Muñoz M, García-Erce JA and Remacha AF: Disorders of iron metabolism. Part 1: Molecular basis of iron homoeostasis. J Clin Pathol. 64:281–286. 2011. View Article : Google Scholar : PubMed/NCBI
8	Chasapis CT, Loutsidou AC, Spiliopoulou CA and Stefanidou ME: Zinc and human health: An update. Arch Toxicol. 86:521–534. 2012. View Article : Google Scholar : PubMed/NCBI
9	Bost M, Houdart S, Oberli M, Kalonji E, Huneau JF and Margaritis I: Dietary copper and human health: Current evidence and unresolved issues. J Trace Elem Med Biol. 35:107–115. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cobanoglu U, Demir H, Sayir F, Duran M and Mergan D: Some mineral, trace element and heavy metal concentrations in lung cancer. Asian Pac J Cancer Prev. 11:1383–1388. 2010.PubMed/NCBI
11	Zowczak M, Iskra M, Torliński L and Cofta S: Analysis of serum copper and zinc concentrations in cancer patients. Biol Trace Elem Res. 82:1–8. 2001. View Article : Google Scholar : PubMed/NCBI
12	Díez M, Arroyo M, Cerdàn FJ, Muñoz M, Martin MA and Balibrea JL: Serum and tissue trace metal levels in lung cancer. Oncology. 46:230–234. 1989. View Article : Google Scholar : PubMed/NCBI
13	Issell BF, MacFadyen BV, Gum ET, Valdivieso M, Dudrick SJ and Bodey GP: Serum zinc levels in lung cancer patients. Cancer. 47:1845–1848. 1981. View Article : Google Scholar : PubMed/NCBI
14	Sweeney JD, Ziegler P, Pruet C and Spaulding MB: Hyperzincuria and hypozincemia in patients treated with cisplatin. Cancer. 63:2093–2095. 1989. View Article : Google Scholar : PubMed/NCBI
15	Wang LS, Lin HY, Chang CJ, Fahn HJ, Huang MH and Lin CF: Effects of en bloc esophagectomy on nutritional and immune status in patients with esophageal carcinoma. J Surg Oncol. 67:90–98. 1998. View Article : Google Scholar : PubMed/NCBI
16	Ganz T: Systemic iron homeostasis. Physiol Rev. 93:1721–1741. 2013. View Article : Google Scholar : PubMed/NCBI
17	Akutsu Y, Kono T, Uesato M, Hoshino I, Murakami K, Fujishiro T, Imanishi S, Endo S, Toyozumi T and Matsubara H: Are additional trace elements necessary in total parenteral nutrition for patients with esophageal cancer receiving cisplatin-based chemotherapy? Biol Trace Elem Res. 150:109–115. 2012. View Article : Google Scholar : PubMed/NCBI
18	Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C and Grubb A: Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem. 38:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
19	Newman DJ: Cystatin C. Ann Clin Biochem. 39:89–104. 2002. View Article : Google Scholar : PubMed/NCBI
20	Chew JS, Saleem M, Florkowski CM and George PM: Cystatin C - a paradigm of evidence based laboratory medicine. Clin Biochem Rev. 29:47–62. 2008.PubMed/NCBI
21	Oc MA, Demir H, Cekmen MB, Isgoren S, Gorur GD and Bilgili U: Correlation of Cystatin-C and radionuclidic measurement method of glomerular filtration rate in patients with lung cancer receiving cisplatin treatment. Ren Fail. 36:1043–1050. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kos FT, Sendur MA, Aksoy S, Sezer S, Civelek B, Yazici O, Yaman S, Eren T and Zengin N: Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy. Ren Fail. 35:705–710. 2013. View Article : Google Scholar : PubMed/NCBI
23	Bodnar L, Wcislo GB, Smoter M, Gasowska-Bodnar A, Stec R, Synowiec A and Szczylik C: Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press Res. 33:360–367. 2010. View Article : Google Scholar : PubMed/NCBI
24	Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, et al: American Society of Clinical Oncology: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol. 24:2932–2947. 2006. View Article : Google Scholar : PubMed/NCBI
25	Bjarnadóttir M, Grubb A and Olafsson I: Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest. 55:617–623. 1995. View Article : Google Scholar : PubMed/NCBI
26	Yamawaki C, Takahashi M, Takara K, Kume M, Hirai M, Yasui H and Nakamura T: Effect of dexamethasone on extracellular secretion of cystatin C in cancer cell lines. Biomed Rep. 1:115–118. 2013.PubMed/NCBI
27	Adamama-Moraitou KK, Saridomichelakis MN, Polizopoulou Z, Kritsepi M, Tsompanakou A and Koutinas AF: Short-term exogenous glucocorticosteroidal effect on iron and copper status in canine leishmaniasis (Leishmania infantum). Can J Vet Res. 69:287–292. 2005.PubMed/NCBI
28	Hodgkinson E, Neville-Webbe HL and Coleman RE: Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol). 18:710–718. 2006. View Article : Google Scholar : PubMed/NCBI
29	Abbasciano V, Mazzotta D, Vecchiatti G, Tassinari D, Nielsen I and Sartori S: Changes in serum, erythrocyte, and urinary magnesium after a single dose of cisplatin combination chemotherapy. Magnes Res. 4:123–125. 1991.PubMed/NCBI
30	Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcisło K and Szczylik C: Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study. Eur J Cancer. 44:2608–2614. 2008. View Article : Google Scholar : PubMed/NCBI
31	Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, Matsumoto S, Ohmatsu H and Ohe Y: Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: A retrospective study. Jpn J Clin Oncol. 44:346–354. 2014. View Article : Google Scholar : PubMed/NCBI